Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of PF-07976016 and Danuglipron in Overweight/Obesity
NCT06910839Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-07976016 in Overweight and obesity, sponsored by Pfizer. Primary endpoints: Steady state area under the concentration-time profile for PF-07976016, Steady state maximum observed concentration for PF-07976016 and 2 more. Started Mar 2025; status: terminated.
02
Drugs
PF-07976016
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT06910839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06910839.